Newsroom

Glenmark Pharmaceuticals receives ANDA approval for Acyclovir Ointment USP, 5%

2 Aug 2017 | Read More

Glenmark Pharmaceuticals Reports Positive Data in a Phase 2a Study of GBR 830 for the Treatment of Patients with Atopic Dermatitis

1 Aug 2017 | Read More

Glenmark’s consolidated revenue increases by 19.99% to Rs. 23,630.02 Mn for Q1 FY 2017 – 18

27 Jul 2017 | Read More

Glenmark receives ANDA approval for Desonide Cream, 0.05%

25 Jul 2017 | Read More

Glenmark Pharmaceuticals Enters Exclusive Agreement with Cyndea Pharma S.L. for Generic Soft-Gelatin Capsule Drug Products

20 Jul 2017 | Read More

Glenmark receives ANDA approval for Amlodipine and Olmesartan Medoxomil Tablets

8 Jul 2017 | Read More

Glenmark Pharmaceuticals receives MHRA Approval for Maloff Protect as Pharmacy license in the UK

4 Jul 2017 | Read More

Glenmark receives ANDA approval for Indomethacin Extended-Release Capsules USP-75mg

29 Jun 2017 | Read More

Glenmark Pharmaceuticals Receives Tentative ANDA Approval For Solifenacin Succinate Tablets, 5 mg and 10 mg

22 Jun 2017 | Read More

Glenmark Pharmaceuticals Licenses Small Molecule Oncology Compound from APC Therapeutics to Expand Immuno-Oncology Portfolio

21 Jun 2017 | Read More

Tentative ANDA approval for Saxagliptin Tablets, 2.5 mg and 5 mg

14 Jun 2017 | Read More

ANDA approval for Atomoxetine Capsules USP, 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg

31 May 2017 | Read More

ANDA approval for Nebivolol Tablets, 2.5 mg, 5 mg, 10 mg and 20 mg

29 May 2017 | Read More

ANDA approval for Olmesartan Medoxomil Tablets, 5 mg, 20 mg and 40 mg

26 May 2017 | Read More

Glenmark Pharmaceuticals to Initiate Clinical Study for GBR 1342

16 May 2017 | Read More

Glenmark's consolidated revenue increased by 6.52% to Rs. 24,571.83 Mn for Q4 FY 2016 -- 17

11 May 2017 | Read More

Glenmark Pharmaceuticals Initiates Clinical Investigation for GBR 310, its Proposed Biosimilar Candidate for XOLAIR®

25 Apr 2017 | Read More

Glenmark Pharmaceuticals receives tentative ANDA approval for Dabigatran Etexilate Capsules, 75 mg, 110 mg and 150 mg

19 Apr 2017 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Fenofibrate Capsules USP, 67 mg, 134 mg and 200 mg

10 Apr 2017 | Read More

Glenmark Pharmaceuticals receives tentative ANDA approval for Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg and 100 mg

31 Mar 2017 | Read More

Glenmark Pharmaceuticals reports positive results from a Phase 3 trial of GSP 301

30 Mar 2017 | Read More

Glenmark Pharmaceuticals receives tentative ANDA approval for Fingolimod Capsules, 0.5 Mg

20 Mar 2017 | Read More

Glenmark Pharmaceuticals Receives FDA Clearance of IND for GSP 304

8 Mar 2017 | Read More

Glenmark Pharmaceuticals and Evestra, Inc. Announce Partnership Agreement for Generic NuvaRing®

2 Mar 2017 | Read More

Glenmark’s consolidated revenue increases by 42.55 % to Rs. 25,350.08 Mn for Q3 FY 2016 – 17

2 Feb 2017 | Read More

Glenmark Pharmaceuticals Receives FDA Clearance of IND for GBR 1302-BEAT™ Phase I Trial

3 Jan 2017 | Read More

Library

Profile – Chairman and Managing Director
+
Profile – Chairman and Managing Director
With the idea of creating something unique, Glenn Saldanha took over the reins of the company and helped transform it into a global enterprise worth USD 1.1 billion with offices across 20 countries. Download Profile
Profile – Glenmark Pharmaceuticals
+
Profile – Glenmark Pharmaceuticals
Research-driven, global and integrated pharmaceutical company which is driven to meet unmet medical needs and help pave a new way for a new world. Download Profile

For any media related queries, please email corpcomm@glenmarkpharma.com